Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?

[1]  K. Reddy,et al.  Final results of a double‐blind, placebo‐controlled trial of the antifibrotic efficacy of interferon‐γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis , 2007, Hepatology.

[2]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[3]  P. Marcellin,et al.  Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin , 2005, European journal of gastroenterology & hepatology.

[4]  Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C , 2005 .

[5]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[6]  K. Bjøro,et al.  Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study , 2004, Hepatology.

[7]  R. Fontana.  Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. , 2004, Gastroenterology clinics of North America.

[8]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[9]  G. Drusano,et al.  A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. , 2004, The Journal of infectious diseases.

[10]  D. Purdie,et al.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life , 2004, Gut.

[11]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[12]  M. Buti,et al.  Extending combination therapy with peginterferon alfa‐2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases , 2003, Hepatology.

[13]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[14]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[15]  H. Bonkovsky,et al.  Iron as a comorbid factor in chronic viral hepatitis , 2002, American Journal of Gastroenterology.

[16]  William M. Lee,et al.  Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C , 2001 .

[17]  S. Zeuzem,et al.  Detection of residual hepatitis C virus RNA by transcription‐mediated amplification in patients with complete virologic response according to polymerase chain reaction–based assays , 2000, Hepatology.

[18]  G. Davis,et al.  Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. , 2000, Gastroenterology.

[19]  C. Garret,et al.  A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. , 1999, Gastroenterology.

[20]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[21]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.